Company news
Karyopharm Therapeutics Inc. news in 2024
Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
December 8, 2024
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
December 2, 2024
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
November 24, 2024
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
November 19, 2024
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
November 17, 2024
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 4, 2024
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
October 30, 2024
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
October 30, 2024
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
October 29, 2024
Karyopharm to Participate at Upcoming Investor Conferences
September 2, 2024
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 5, 2024
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
May 31, 2024
Karyopharm to Participate at the Jefferies Global Healthcare Conference
May 28, 2024
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
May 7, 2024
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 7, 2024
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
May 7, 2024
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
May 1, 2024
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
April 23, 2024
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
March 5, 2024
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
February 21, 2024
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
January 7, 2024
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Calls in 2024
- Karyopharm Therapeutics (NASDAQ:KPTI) Q3 2024 Earnings Call
Nov 5, 2024
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q2 2024 Earnings Call
Aug 6, 2024
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q1 2024 Earnings Call
May 8, 2024
Transcript - Karyopharm Therapeutics (NASDAQ:KPTI) Q4 2023 Earnings Call
Feb 29, 2024
Transcript